Attention deficit hyperactivity disorder: Pharmacologic management in children and adolescents

Gabriel Kaplan, Jeffrey H. Newcorn, Iliyan S. Ivanov

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Attention deficit hyperactivity disorder (ADHD) used to be considered a mild childhood condition that manifested mostly in the school setting and remitted by adolescence. More recently, a large body of evidence has shown that it is a very frequent psychiatric problem in childhood, causes considerable suffering in patients and their families, and persists in adulthood 70% of the time. This chapter outlines current pharmacological treatment options available to office based clinicians who wish to provide treatment for ADHD. Each FDA approved agent is reviewed in detail focusing on the safety profile and efficacy data, as well as the monitoring tools that can be utilized to optimize treatment. This review also addresses recent controversies in the field and provides practical clinical advice within a Frequently Asked Question format.

Original languageEnglish
Title of host publicationClinical Aspects of Psychopharmacology in Childhood and Adolescence
PublisherNova Science Publishers, Inc.
Number of pages27
ISBN (Electronic)9781611227154
ISBN (Print)9781611221350
StatePublished - 1 Jan 2011


Dive into the research topics of 'Attention deficit hyperactivity disorder: Pharmacologic management in children and adolescents'. Together they form a unique fingerprint.

Cite this